Opinion: Editor’s note: This opinion piece is now outdated

There is little doubt the Grail cancer test will engender more testings. But what we really want to know is whether getting the test helps people live longer or live…
Source: Simon Dawson/Getty Images

Editor’s note: STAT regrets publishing this First Opinion because we learned after publication that its central premise is wrong, through no fault of the with the National Health Service described it as a partnership that would include 140,000 healthy people. It did not call it a study or specify that patients would be randomized and that there would be a control group. The said these 140,000 participants will have annual blood tests for three years. On January 28, 2021, after this article had been submitted to STAT, the president of Grail Europe  that responded to  on the Grail-NHS partnership. The letter disclosed that Grail and the NHS planned to conduct a “pragmatic, controlled study” of the Grail test with randomization. Unfortunately, neither the authors of this piece nor STAT editors saw the letter before publishing the piece on Feb. 12. Grail spokesman Matt Burns told STAT on Feb. 13 that participants would be randomized 1:1 to the study’s two arms, with 70,000 getting the Grail test and 70,000 not getting it. 

Vous lisez un aperçu, inscrivez-vous pour en lire plus.

Plus de STAT

STAT1 min de lectureMedical
STAT+: Pharmalittle: Novavax Faces Raw-materials Shortages For Covid-19 Shot; India Curbs Vaccine Exports
Novavax is delaying signing a contract to supply its Covid-19 vaccine to the European Union because the company is struggling to source raw materials.
STAT1 min de lectureMedical
STAT+: Pharmalittle: J&J Seeks Emergency Use For Its Coronavirus Vaccine; Merck Says Parasite Drug Does Not Work On Covid-19
Johnson & Johnson has applied to the FDA for an emergency use authorization for its one-dose Covid-19 vaccine, setting in motion a process all but sure to see a third…
STAT1 min de lectureMedical
STAT+: Pharmalittle: Single Pfizer Shot Is 85% Effective In Preventing Symptomatic Covid-19; Biden To Commit $4 Billion To COVAX
An Israeli study found that a single shot of the Covid-19 vaccine from Pfizer (PFE) and BioNTech (BNTX) is 85% effective in preventing symptomatic disease.